Prosecution Insights
Last updated: October 04, 2026
Application No. 18/576,580

FUNGICIDAL USE

Final Rejection §102§103§DP
Filed
Jan 04, 2024
Priority
Jul 08, 2021 — provisional 63/219,703 +1 more
Examiner
SEAMAN, D MARGARET M
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
ADAMA Agricultural Solutions Ltd.
OA Round
3 (Final)
76%
Grant Probability
Favorable
4-5
OA Rounds
0m
Est. Remaining
84%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allowance Rate
1075 granted / 1405 resolved
+16.5% vs TC avg
Moderate +8% lift
Without
With
+8.0%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 2m
Avg Prosecution
46 currently pending
Career history
1424
Total Applications
across all art units

Statute-Specific Performance

§101
4.4%
-35.6% vs TC avg
§103
16.0%
-24.0% vs TC avg
§102
19.9%
-20.1% vs TC avg
§112
35.8%
-4.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1405 resolved cases

Office Action

§102 §103 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This application was filed 01/04/2024. Non-Final rejection was mailed 03/27/2026. Applicant responded on 06/29/2026 and amended the claims such that claims 1 and 41-49 are before the Examiner. Claim Rejections - 35 USC § 102 The previous rejection of claims 1 and 41-49 under 35 U.S.C. 102(a)(2) as being anticipated by WO2012/025912 is being changed to a rejection under 35 U.S.C. 103 as follows. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1 and 41-49 are rejected under 35 U.S.C. 103 as being unpatentable over WO 2012/025912. WO teaches fungicidal compositions of multiple fungicides to treat fungal infestations on crops. The combination of fungicides have synergistic activity (abstract). The fungicide is a phthalimide fungicide. Folpet and captan are specifically taught in paragraph 19 as two of 5 phthalimide fungicides. 45 different crops are taught by the WO as being treated by this synergistic combination which include apple, banana and olive in paragraph 36. The phytopathogenic fungi are taught in paragraphs 39-40 which include the instantly claimed fungi. The rate applied is taught in paragraphs 41-43. Paragraph 49 teaches that the combination can include a suspension. Granules and their formulation is taught in paragraph 52. The advantage as taught by the WO is that the composition has a synergistic effect which improves the quality of harvested crops. It would have been obvious to one of ordinary skill in the art at the time of the invention to use the synergistic combination of captan and folpet as instantly claimed to treat the olive, apple and banana crops from the fungi instantly claimed. Rationale: The combination of the two or more fungicides is taught to be synergistic. The crops taught by the prior art. The fungi to be treated are taught by the prior art. The use of a known combination to treat a known phytopathogenic fungi on a known crop is within the skill of the ordinary artisan. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. The rejection of claims 1 and 41-49 provisionally on the ground of nonstatutory double patenting as being unpatentable over claims of copending Application No. 18/725998 (USPGPub20250089720) and copending Application No. 18/004603 (USPGPub20230270113) (reference application), is upheld. Although the claims at issue are not identical, they are not patentably distinct from each other because the same combination of fungicides (captan and folpet) are used to treat the same fungal infestation on the same crops, banana and olives. Same combination. Same crops. Same fungus. Applicant offered no argument to this rejection in paper dated 08/24/2026. This rejection is upheld. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to D MARGARET M SEAMAN whose telephone number is (571)272-0694. The examiner can normally be reached M-F 8am-4pm Eastern. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /D MARGARET M SEAMAN/Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Jan 04, 2024
Application Filed
Mar 27, 2026
Non-Final Rejection mailed — §102, §103, §DP
Jun 29, 2026
Response Filed
Jul 15, 2026
Non-Final Rejection mailed — §102, §103, §DP
Aug 24, 2026
Response Filed
Sep 04, 2026
Final Rejection mailed — §102, §103, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747211
METHODS OF MAKING NICOTINIC ACID DERIVATIVES
3y 5m to grant Granted Sep 29, 2026
Patent 12741939
COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHIES
3y 6m to grant Granted Sep 22, 2026
Patent 12741937
A TAUTOMERIC LIGAND ENABLES BIOMIMETIC C-H HYDROXYLATION WITH MOLECULAR OXYGEN
3y 3m to grant Granted Sep 22, 2026
Patent 12692235
FUSED RING COMPOUND AND APPLICATION THEREOF
4y 0m to grant Granted Jul 28, 2026
Patent 12692276
TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS
3y 1m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
76%
Grant Probability
84%
With Interview (+8.0%)
2y 2m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1405 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month